Table 4.
Univariate analyses of the impact on overall survival in patients with CN-AML who received intensive induction chemotherapy
| Variable |
No. of patients |
Overall survival |
|
|---|---|---|---|
| Mediana | P | ||
| Age, years |
|
|
0.001* |
| 60 or younger |
66 |
32.2 |
|
| Older than 60 |
22 |
4.5 |
|
| WBC |
|
|
0.469 |
| 50000/uL or less |
49 |
31.433 |
|
| Greater than 50000/uL |
37 |
13 |
|
|
BDH2 |
|
|
0.007* |
| Lower expression |
46 |
53.667 |
|
| Higher expression |
40 |
9 |
|
|
CEBPA |
|
|
0.755 |
| Double mutation |
9 |
31.433 |
|
| Single mutation |
16 |
53.667 |
|
| No mutation |
61 |
16.267 |
|
|
NPM1 |
|
|
0.179 |
| Mutated |
28 |
10.4 |
|
| Wild |
58 |
32.2 |
|
|
FLT3-ITD- |
|
|
<0.001* |
| Mutated |
17 |
4.767 |
|
| Wild |
70 |
48.633 |
|
|
FLT3-TKD |
|
|
0.596 |
| Mutated |
7 |
13.00 |
|
| Wild |
79 |
18.567 |
|
|
NPM1/FLT3-ITD |
|
|
0.314 |
| NPM1+/FLT3-ITD- |
15 |
NR |
|
| Others |
71 |
15.067 |
|
|
IDH1b |
|
|
0.796 |
| Mutated |
3 |
22.21 |
|
| Wild |
61 |
27.055 |
|
|
IDH2b |
|
|
0.749 |
| Mutated |
4 |
21.91 |
|
| Wild |
60 |
27.16 |
|
|
DNMT3Ab |
|
|
0.508 |
| Mutated |
11 |
32.58 |
|
| Wild |
53 |
25.63 |
|
|
MLLb |
|
|
0.178 |
| Mutated |
5 |
12.63 |
|
| Wild |
59 |
13.12 |
|
|
BDH2low/FLT3-ITD |
|
|
<0.001* |
| BDH2low/FLT3-ITDwild type |
40 |
722.16 |
|
| BDH2low/FLT3-ITDmutation |
5 |
519.73 |
|
| BDH2high/FLT3-ITDwild type |
27 |
371.56 |
|
| BDH2high/FLT3-ITDmutation | 13 | 182.27 | |
Abbreviation: NR indicates not reached.
aMedian, months.
bOnly 64 patients who had high quality DNA preserved for sequence received standard intensive induction chemotherapy.
*Statistically significant (P < 0.05).